Hainan Huluwa Pharmaceutical Group Past Earnings Performance
Past criteria checks 0/6
Hainan Huluwa Pharmaceutical Group's earnings have been declining at an average annual rate of -10.6%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 15.1% per year. Hainan Huluwa Pharmaceutical Group's return on equity is 8.6%, and it has net margins of 5.3%.
Key information
-10.6%
Earnings growth rate
-13.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 15.1% |
| Return on equity | 8.6% |
| Net Margin | 5.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Hainan Huluwa Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,808 | 95 | 702 | 94 |
| 31 Dec 23 | 1,905 | 106 | 756 | 94 |
| 30 Sep 23 | 1,736 | 91 | 663 | 68 |
| 30 Jun 23 | 1,696 | 89 | 673 | 73 |
| 31 Mar 23 | 1,643 | 96 | 677 | 90 |
| 31 Dec 22 | 1,515 | 86 | 654 | 106 |
| 30 Sep 22 | 1,500 | 67 | 710 | 133 |
| 30 Jun 22 | 1,456 | 78 | 683 | 122 |
| 31 Mar 22 | 1,444 | 78 | 665 | 122 |
| 31 Dec 21 | 1,354 | 72 | 616 | 100 |
| 30 Sep 21 | 1,259 | 124 | 548 | 75 |
| 30 Jun 21 | 1,217 | 131 | 542 | 72 |
| 31 Mar 21 | 1,211 | 128 | 558 | 56 |
| 31 Dec 20 | 1,162 | 122 | 552 | 52 |
| 30 Sep 20 | 1,250 | 148 | 584 | 50 |
| 30 Jun 20 | 1,271 | 122 | 597 | 53 |
| 31 Mar 20 | 1,289 | 120 | 746 | 61 |
| 31 Dec 19 | 1,306 | 120 | 620 | 52 |
| 31 Dec 18 | 984 | 101 | 436 | 43 |
| 31 Dec 17 | 655 | 22 | 245 | 20 |
| 31 Dec 16 | 487 | 34 | 130 | 11 |
Quality Earnings: 605199 has a high level of non-cash earnings.
Growing Profit Margin: 605199's current net profit margins (5.3%) are lower than last year (5.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605199's earnings have declined by 10.6% per year over the past 5 years.
Accelerating Growth: 605199's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 605199 had negative earnings growth (-1.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 605199's Return on Equity (8.6%) is considered low.